

Special Issue

New Advances and Challenges in Multiple Sclerosis: Pathophysiology and Therapeutic Strategies

Message from the Guest Editor

Multiple sclerosis (MS) is the most common neurological disease, being especially dramatic for debuting mainly in young adults and for not having a cure. The treatments address the immune component of the disease, are mostly effective in the relapsing-remitting MS variant, and are almost totally ineffective in the progressive forms of MS. Therefore, the search for molecular/cellular factors capable of differentiating at the pathophysiological level the intrinsic reasons for these differences, is of vital importance in the search for new treatments for people with MS. On the other hand, the existence of recovery phases in RRMS patients points to the existence of spontaneous self-correcting phenomena of the inflammatory episode that lead to neuro-repair of the damaged tissue. The aim of this Special Issue of *Biomedicines* is to provide an overview of the pathophysiologic role of newer and older molecular mechanisms of MS together with the presentation of insights for the consecution of new therapeutic strategies. Moreover, it will focus on biomarkers to help in the accurate disease monitoring. Both original articles and reviews will be considered for publication in this Issue.

Guest Editor

Dr. Diego Clemente

Neuroimmuno-Repair Group, National Hospital for Paraplegics, 45071 Toledo, Spain

Deadline for manuscript submissions

closed (30 June 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/93504

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).